TransCode Therapeutics making preclinical progress with lead metastatic cancer candidate

June 28, 2023 at 15:49 PM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

--News Direct--

TransCode Therapeutics CEO Michael Dudley joined Proactive's Natalie Stoberman to share the latest progress from its lead RNA oncology candidate TTX-MC138. TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics.

The company has created a platform of drug candidates designed to target a variety of tumour types with the objective of significantly improving patient outcomes. TransCode's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which is believed to cause approximately 90% of all cancer deaths totalling over nine million per year worldwide.

Contact Details

Proactive USA

+1 347-449-0879

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/transcode-therapeutics-making-preclinical-progress-with-lead-metastatic-cancer-candidate-175829166

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol	Price	Change (%)
AMZN	234.11	+1.32 (0.57%)
AAPL	294.30	-2.71 (-0.91%)
AMD	519.85	-31.78 (-5.76%)
BAC	57.91	+0.54 (0.94%)
GOOG	346.08	-2.70 (-0.77%)
META	562.20	-1.65 (-0.29%)
MSFT	373.94	+6.60 (1.80%)
NVDA	200.04	-8.61 (-4.13%)
ORCL	165.16	-9.91 (-5.66%)
TSLA	381.61	-23.44 (-5.79%)

Symbol

Price

Change (%)

AMZN

234.11

+1.32 (0.57%)

AAPL

294.30

-2.71 (-0.91%)

AMD

519.85

-31.78 (-5.76%)

BAC

57.91

+0.54 (0.94%)

GOOG

346.08

-2.70 (-0.77%)

TransCode Therapeutics making preclinical progress with lead metastatic cancer candidate

Contact Details

More News

Recent Quotes